Treatment With rt-PA Within Six Hours of Stroke Beneficial

Randomized trial, meta-analysis show benefit for wide range of patients with acute ischemic stroke

WEDNESDAY, May 23 (HealthDay News) -- For patients with acute ischemic stroke, treatment with recombinant tissue plasminogen activator (rt-PA) within six hours is associated with improved outcomes, according to two studies published online May 23 in The Lancet to coincide with presentation at the European Stroke Conference, held from May 22 to 25 in Lisbon, Portugal.

Peter Sandercock, D.M., from the University of Edinburgh in the United Kingdom, and colleagues conducted the third International Stroke Trial involving a wide range of patients (3,035) with acute ischemic stroke, enrolled in 156 hospitals in 12 countries. Participants (of whom 53 percent were older than 80 years) were randomly allocated to receive rt-PA within six hours of stroke (1,515 patients) or to control (1,520 patients). At six-months, the researchers observed no significant difference in the percentage of patients alive and independent (37 percent in the rt-PA group versus 35 percent in the control group). A significant shift in Oxford Handicap Scores was seen on ordinal analysis (common odds ratio [OR], 1.27).

In a second study, Joanna M. Wardlaw, M.D., also from the University of Edinburgh, and colleagues conducted an updated systematic review and meta-analysis which included 12 trials involving 7,012 patients given rt-PA within six hours of onset of acute ischemic stroke. The researchers found that rt-PA was associated with significantly increased odds of being alive and independent (modified Rankin scale 0 to 2) at the final follow-up (OR, 1.17). Patients treated within three hours received the greatest benefit (OR, 1.53).

"The data strengthen previous evidence to treat patients as early as possible after acute ischemic stroke, although some patients might benefit up to six hours after stroke," Wardlaw and colleagues conclude.

Several authors from both studies disclosed financial ties to the pharmaceutical industry.

Abstract - Sandercock
Full Text (subscription or payment may be required)
Abstract - Wardlaw
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
More Information

Copyright © 2012 HealthDay. All rights reserved.

Powered by

Featured Jobs



Benefits of Membership

FREE E-Newsletters
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues

CESaver
Join our CESaver program to earn up to 100 contact hours for only $34.95
Register Now

Lippincott's NursingCenter.com
Explore a world of online resources

Become a Member